Non-Classic CAH vs PCOS: The Look-Alike Found in 1 in 24 Hyperandrogenic Women

First, the name

In May 2026 a global consensus of more than 50 organisations renamed PCOS polyendocrine metabolic ovarian syndrome, or PMOS, in The Lancet. Nothing about the diagnostic criteria changed, including the requirement to rule out non-classic CAH before either label goes on a chart. This article uses “PCOS” because that is still what shows up on referral letters and in search.

Why NCCAH looks exactly like PCOS on paper

Non-classic congenital adrenal hyperplasia and PCOS produce the identical three-item list — irregular cycles, acne, excess hair growth — because both are androgen-excess conditions built from different machinery. PCOS raises androgens mainly from the ovary, often alongside insulin resistance. NCCAH raises them from the adrenal gland, through a partial deficiency in the enzyme 21-hydroxylase, encoded by the gene CYP21A2. The enzyme shortage blocks cortisol production at one step, and the backed-up precursor gets shunted into androgen synthesis instead. Two different organs, two different pathways, one identical-looking patient in the waiting room.

Every version of the PCOS criteria — 1990 NIH, 2003 Rotterdam, 2006 AE-PCOS, and the 2023 international guideline — requires this condition to be excluded before a PCOS diagnosis is made. That instruction is easy to write into a guideline and easy to skip in a ten-minute appointment, which is exactly how the overlap survives.

How often is it actually NCCAH instead of PCOS?

A 2017 systematic review and meta-analysis put the worldwide prevalence of NCCAH at 4.2% (95% CI 3.2–5.4%) among women presenting with signs of androgen excess — hirsutism, acne, irregular cycles, the same list PCOS is built from. A single-country study in Spain, prospectively testing 270 consecutive women with hyperandrogenic symptoms, found NCCAH in 2.2% of them, all six cases confirmed by CYP21A2 genotyping.

That same 2017 review notes that ethnicity moves the number substantially, because 21-hydroxylase deficiency is a recessive condition and some populations carry the CYP21A2 mutation far more often than others. That variation is why published estimates range from roughly one in fifty to closer to one in ten depending on which population was screened. There is no single global figure — there is a range, and where a given patient sits in it depends on ancestry, not on how “textbook” her symptoms look.

The one test that actually separates them: 17-hydroxyprogesterone

A single hormone test does most of the work here. 17-hydroxyprogesterone (17-OHP) sits directly upstream of the enzyme block in NCCAH, so it backs up in the blood when that enzyme is short-staffed — and it does not, in the same way, in PCOS. The 2017 review states the standard interpretation plainly: a basal morning 17-OHP at or above 2 ng/mL should trigger further testing, and a level at or above 10 ng/mL — basal or after a cosyntropin (ACTH) stimulation test — is considered definitive.

Three things make this test easy to get wrong in practice. It has to be drawn in the morning, because 17-OHP follows a daily rhythm and an afternoon sample can read falsely low. It ideally needs the follicular phase of the cycle, if periods are happening at all. And, exactly as with androgen testing for PCOS diagnostic criteria itself, combined hormonal contraceptives suppress the adrenal-ovarian axis enough to distort the result.

A borderline basal result — high enough to raise suspicion, not high enough to confirm — is what the cosyntropin stimulation test exists for. It measures 17-OHP again 30 to 60 minutes after a synthetic ACTH injection, which pushes the adrenal gland to reveal whatever the basal draw missed.

What “late-onset CAH” means, and whether it’s a different condition

It isn’t. Late-onset CAH, attenuated CAH, and non-classic CAH are three names for the same diagnosis — the milder end of 21-hydroxylase deficiency that presents after infancy rather than at birth. That is worth saying plainly, because the inconsistent naming in the wider literature causes real confusion for anyone researching their own results. Classic CAH — the severe, salt-wasting or simple-virilizing form — is caught on newborn screening in most high-income countries and looks nothing like an adult hyperandrogenism work-up. Non-classic CAH has enough residual enzyme activity that it stays silent until puberty, early adulthood, or later, which is precisely the window where it gets folded into a PCOS diagnosis instead of investigated on its own terms.

The severity spectrum behind “classic” and “non-classic”

Three forms of 21-hydroxylase deficiency sit on one severity spectrum, and non-classic is the mild end of it, not a separate disease. The Endocrine Society’s clinical practice guideline for this condition covers all three, because they share one gene and one enzyme, and differ only in how much working enzyme is left.

That last row is the entire reason this overlap exists: non-classic disease leaves enough enzyme function that nothing looks abnormal at birth, and newborn screening — built to catch the salt-wasting form — is not designed to flag it. The condition stays invisible until androgen signs appear later in life, at exactly the age when a PCOS work-up is the more familiar path for a clinician to reach for.

Why getting this right changes what happens next

A missed NCCAH diagnosis is not a semantic loss. It changes three concrete things.

Genetic counselling. Because 21-hydroxylase deficiency is autosomal recessive, most people with confirmed NCCAH carry at least one severe CYP21A2 allele — meaning a future pregnancy with a partner who also carries a severe allele carries a real risk of classic CAH in the child. That conversation does not happen while the diagnosis stays “PCOS.”

Fertility management. Women with NCCAH carry a higher miscarriage risk that glucocorticoid treatment during pregnancy can reduce — a treatment with no place in a standard PCOS fertility plan and one that is never offered under that label.

Treatment choice. Combined oral contraceptives and anti-androgens treat the cosmetic and cycle symptoms of both conditions reasonably well, which is part of why the overlap goes unnoticed for years — the wrong diagnosis can still respond to treatment. Confirmed NCCAH is also managed under its own dedicated Endocrine Society guideline, separate from anything written for PCOS, including glucocorticoid replacement that addresses the enzyme block directly — an option a PCOS-only work-up never puts on the table.

Who should actually ask for the 17-OHP test

Testing everyone with hyperandrogenic symptoms for NCCAH is not what any guideline recommends, and it is not necessary. Ask for it specifically if any of the following apply: androgen signs (pubic hair, body odour, rapid growth) appeared before the usual age of puberty; a sibling, parent, or close relative has diagnosed CAH, unexplained recurrent miscarriage, or very early puberty; ancestry traces to a population with a known higher carrier frequency for CYP21A2 mutations (several Mediterranean, Ashkenazi Jewish, and South Asian populations are among those studied); or standard PCOS treatment — combined contraceptives, metformin, anti-androgens — has produced little improvement after a reasonable trial.

Where this distinction does not change anything

If androgen signs started in the twenties, no early relative history exists, ancestry does not point to a higher-carrier-frequency population, and a basal 17-OHP has already come back clearly low, pursuing further CAH testing has low yield. In that situation, the two-of-three Rotterdam evaluation covered on PCOS diagnostic criteria is doing its job, and NCCAH is not the missing piece. The point of this page is not to turn every hirsutism case into a CAH work-up — it is to make sure the one test that rules it out actually gets ordered once, which the guidelines already require and daily practice sometimes skips.

If results genuinely fit neither pattern — androgens normal, cycles irregular, ultrasound unremarkable — that combination has its own explanation worth reading. When the ovaries themselves are the sticking point, PCOS without the follicle count that gives the condition its name is common enough to have its own page too. And if cycles are the normal-looking piece instead, PCOS with regular periods covers that combination on its own terms.

What to ask for at your next appointment

Start with three questions, in this order: has non-classic CAH specifically been excluded, or only assumed unlikely; was a basal 17-hydroxyprogesterone drawn in the morning, and if so what number came back; and if it was borderline, has a cosyntropin stimulation test been discussed. The full PCOS blood test panel already includes 17-OHP as a baseline exclusion test — the goal is confirming it was actually run, not just listed. The rest of the diagnosis section covers every other step in that work-up.